End-to-End Enrollment
Top-of-Funnel Recruitment
Global Impact: With millions struggling to quit vaping, cessation trials are essential to uncover what works. Understanding behavioral triggers, testing new therapies, and improving quit rates can help prevent long-term health consequences. These studies don’t just help individuals—they shape public health strategies for a healthier future. This was a wide-reaching study seeking to enroll at least 230 patients across the United States, Canada, France, Germany, and the UK. They had to be at least 18 years old, using nicotine for the past three months, and willing to become nicotine-free.
Enrollment Bottleneck: Through the first half of this eight-week campaign, we noticed that enrollment rates were lower than expected at just 3.55% of all submissions. We also saw that 61.00% of all participants had begun the submission process but exited the enrollment journey before completing the screener. That number was nearly double the amount of patients (35.55%) who were disqualified immediately.
Optimize Everything: We A/B tested new ways to frame the pre-screening questionnaire so that participants could learn more quickly if they were qualified for the study. This led to twice as many disqualifications, but allowed our screening team more time to spend with higher-qualified patients mid-funnel. Enrollment jumped from 3.55% to 15.80% for the second half of the study.
Enrollment Exceeding Expectations: The enrollment expectation was for 230 participants, but by optimizing mid-funnel steps we were able to deliver 357 patients who completed the enrollment journey. The long-term risks of vaping are still unfolding, yet millions remain addicted. Cessation trials help uncover the most effective treatments, from behavioral interventions to pharmacotherapy, ensuring individuals have the best chance to quit successfully. 1nHealth is proud to be a part of clinical research today that shapes the health outcomes of tomorrow.
